Higher secukinumab dose yields no clinical difference after inadequate response in AS

Dataemia

Higher secukinumab dose yields no clinical difference after inadequate response in AS

A study found that patients with ankylosing spondylitis who had an inadequate response to secukinumab at 16 weeks did not see any additional benefit at 52 weeks from an escalated dose. No new safety signals were observed during the study. The study followed up on a previous phase 4 trial, ASLeap, where patients with AS demonstrated inadequate response after 16 weeks of secukinumab. Results showed that both the standard dose and escalated dose gr…